MBGH-Midwest Business Group on Health Employer Forum, Pharmacy Benefits and Specialty Drugs
–
MBGH Conference: June 22, 2022 from 9:00am to 4:00pm (CT) in Chicago, IL
D2 is attending MBGH Conference, June 22nd in Chicago, IL.
Make plans to connect with our team. We look forward to seeing you there!
What D2 Solutions has to offer.
D2’s Kirby Eng is attending and speaking during a panel discussion on “New Legislation and How Employers will Pay for High-cost Gene Therapies”.
Learn how D2’s technology solutions can address patient friction points and reduce administrative burdens, June 22nd, in Chicago. We look forward to seeing you there!

Manufacturer Services
Commercialization, Trade and Distribution, Market Access and Reimbursement

Pharmacy Services
Accreditation, Regulations, Licensing, Build-Out, Operations

Patient Services
Technology Solutions for Patient Engagement and Adherence
Let's Meet
Provide the information below and we’ll connect you with one of our Subject Matter Experts.BY THE NUMBERS
Manufacturer Services
Working with D2 will ensure successful launch, market presence, leading to patient compliance.
63%
of US bio pharma launches since 2019 driven by D2 Solutions
>40%
of US pharmaceutical product launches since 2019
350+
pharma manufacturing clients have launched products and gained successful market entry
Pharmacy Services
Working with D2 will ensure that your Pharmacy will stay in compliance and be a viable part of prescription distribution.
100+
industry build out facilities
75%
of the Top 50 Specialty Pharmacies use D2 Solutions to support licensing, accreditation and regulatory compliance and operations
350+
successful accreditations, including URAC, ACHC, VIPPs, VAWD, Joint Commission, NABP, CPPA
Patient Services
Providing technology driven services that alleviate barriers to prescription adherence to get patient on medications faster and keeping then on treatment – improving channel performance and health outcomes.
13 years
of pharmaceutical industry experience
83%
patient enrollment for one orphan drug manufacturer
75%
reduction in hub labor costs
15%
acceleration in A/R for one specialty pharmacy